Biotechnology
EpiVax Secures Additional Funding from FDA for Immunogenicity Risk Assessment for Biosimilar Products
PROVIDENCE, R.I., Sept. 13, 2022 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") is pleased to announce the award of a two-year,$2 million grant from the FDA's Office of Center for Drug Evaluation and Research (CDER) to validate a method for immunogenicity risk assessment of host cell proteins (HCP) for ...
2022-09-13 00:24
2664
Himalaya Therapeutics Announces Interim Phase 2 Results for Mecbotamab vedotin (HTBA3011)
* Preliminary observations in Non-Small Cell Lung Cancer ("NSCLC") support advancing to the registrational stage of the trial; anticipate full interim data set in 4Q'22 * Undifferentiated Pleomorphic Sarcoma ("UPS") and osteosarcoma will advance to Phase 2, part 2 enrollment, which is anticip...
2022-09-12 23:32
3115
Brain Navi Biotechnology Announced Partnership with Distributor, Medtreq Medical Equipment, to enter the Middle East and Egypt with NaoTrac Neurosurgical Robot
HSINCHU, Sept. 12, 2022 /PRNewswire/ -- Brain Navi, the leading surgical robot manufacture inTaiwan, announced a strategic partnership with distributor, Medtreq Medical Equipment, to expand the distribution of the Surgical Navigation Robot, NaoTrac, throughout the region of GCC region,Jordan, Egy...
2022-09-12 08:31
3741
MGI Celebrates Grand Opening of Its New State-of-the-Art Demo Lab in Japan
TOKYO, Sept. 9, 2022 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a global life science leader and innovator, announced today on its first day of IPO inChina the grand opening of a new demonstration laboratory inTokyo, Japan, enhancing Japanese customers' experience. MGI has been expanding the oper...
2022-09-09 09:00
3379
KAZIA TO PRESENT FINAL DATA FROM PAXALISIB PHASE II STUDY IN GLIOBLASTOMA AT ESMO
SYDNEY, Sept. 9, 2022 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation a...
2022-09-09 06:00
4756
YishengBio Received Approvals From Philippines and UAE For Phase 2 / 3 Clinical Trials of PIKA Recombinant COVID-19 vaccine
BEIJING, Sept. 8, 2022 /PRNewswire/ -- YishengBio Co., Ltd., ("YishengBio"), a biopharmaceutical company dedicated to discovery, development, manufacturing and commercialization of new generations of vaccines and therapeutic biologics, announced that the Company received the approvals from the re...
2022-09-08 21:33
3186
Nutromics raises US$14 million for its ground-breaking wearable diagnostic platform
MELBOURNE, Australia and SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Global MedTech start-up Nutromics has raised an additional US$14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics' continued expansion acrossAustralia and the United States. Strategic in...
2022-09-08 20:54
4724
ONE DRUG FOR ONE BUG: DEBIOPHARM TO DISCUSS THE POTENTIAL OF PATHOGEN-SPECIFIC ANTIBIOTICS AT THE 2022 WORLD AMR CONGRESS
* International health authorities, such as the WHO and the CDC are warning of the emerging danger of bacterial infections resistant to current antibiotics * The 2022 World Anti-Microbial Resistance (AMR) Congress in the greater Washington D.C. area is serving as a forum to openly address the ...
2022-09-08 16:41
2293
Cytiva launches BioChallenge in Southeast Asia to support biotech startup development
* Cytiva's BioChallenge launches in Singapore, Indonesia, Thailand and Vietnam to accelerate the growth of promising emerging biotechs * BioChallenge facilitates access to Cytiva's services and expertise to scale up efficiently, mitigate risks and reduce time to go to market * Application pe...
2022-09-08 15:31
3152
The Outbreak of COVID-19 Unlocked the Demand for Antimicrobial Technologies
Innovations triggered by the pandemic are pushing industries to adopt long-lasting antimicrobial technology, says Frost & Sullivan SAN ANTONIO, Sept. 8, 2022 /PRNewswire/ -- The outbreak of COVID-19 unlocked the demand for antimicrobial technologies across sectors, finds Frost & Sullivan's recen...
2022-09-08 15:12
2265
Innovent's Sintilimab plus Chemotherapy Demonstrated PFS Benefit in Patients with EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Second Interim Analysis Results of the ORIENT-31 Study
ROCKVILLE, Md. and SUZHOU, China, Sept. 8, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology...
2022-09-08 08:05
4569
Sangel Capital Founder Receives Title of China's Top Early-Stage Investor from ChinaVenture Awards
SHENZHEN, China, Sept. 7, 2022 /PRNewswire/ -- Sangel Capital ("Sangel" or the "Company"), a leading biotech and healthcare venture capital company based in China, has announced that Liu Mulong, Founding Partner with the Company, has been awarded as one ofChina's top early-stage investors of 2021 ...
2022-09-07 23:30
3847
NOVAMONT GROUP: NEW CEO FOR OUR 100% OWNED BIOBAG GROUP
NOVARA, Italy, and ASKIM, Norway, Sept. 7, 2022 /PRNewswire/ -- The Board of BioBag International AS has appointed Patrik Fogelström as new CEO of the BioBag Group and Managing Director of the parent company BioBag International AS, which from 2021 are part of Novamont Group, an international lea...
2022-09-07 21:07
6193
TikoMed's drug candidate ILB® inhibited infection of human cells by Dengue, Zika and Yellow Fever viruses in vitro, providing further support for its broad spectrum mechanism of action
VIKEN, Sweden, Sept. 7, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study examining the ability of the company's lead drug candidate ILB® to inhibit infection of human cells by four serotypes of Dengue virus (DENV1-4), two strains of Zika virus (African a...
2022-09-07 14:32
3233
Non-invasive skin immune biomarker test helps predict development of eczema in babies, new study presented at the EADV Congress finds
MILAN, Sept. 7, 2022 /PRNewswire/ -- Researchers have identified an immune biomarker in newborns that can predict the subsequent onset and severity of paediatric atopic eczema, a new study presented at the 31st European Academy of Dermatology and Venereology (EADV) Congress has shown. The Barrie...
2022-09-07 06:01
4355
Hummingbird Bioscience to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
SAN FRANCISCO, Sept. 6, 2022 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive OfficerPiers Ingram, Ph.D., and Chief Financial Office...
2022-09-06 20:00
2811
Innovent Announces First Participant Dosed in the Higher-dose Cohort of a Phase 2 Clinical Trial of Mazdutide in Chinese Adults with Obesity
ROCKVILLE, Md. and SUZHOU, China, Sept. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune, ophthalmology and ...
2022-09-05 08:00
4002
Aston Sci. Receives IND Approval from U.S. FDA for Phase 2 Clinical Trial of the Therapeutic Cancer Vaccine AST-301 in Patients with HER2 1+/2+ Breast Cancer
- CornerStone-001(NCT05163223), the multiregional clinical trial for breast cancer treatment, received U.S. FDA approval for Phase 2 trial following the approvals inAustralia and the Taiwan region. - As the same patient group and design of a pivotal study are adopted, a placebo-controlled randomi...
2022-09-05 07:00
2633
Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma
* XPOVIO® (selinexor) is the first and only selective inhibitor of nuclear export (SINE) inhibitor approved by the Therapeutic Goods Administration (TGA) ofAustralia for patients with relapsed and/or refractory multiple myeloma (R/R MM) and intriple class refractory R/R MM. * XPOVIO® is the f...
2022-09-01 08:30
4360
Brii Biosciences Appoints Taiyin Yang to Board of Directors, Strengthening Product Quality Oversight to Support Company Momentum
Addition increases diversity of Board governance and supports further
independent expertise
DURHAM, N.C. and BEIJING, Sept. 1, 2022 /PRNewswire/ -- Brii Biosciences
2022-09-01 07:30
3920
Week's Top Stories
Most Reposted
DayOne Secures Over 1GW Renewable Energy in Malaysia in Landmark TNB Partnership
[Picked up by 303 media titles]
2026-06-04 23:55
Amartha Initiates Coalition to Advance Financial Health for Grassroots Communities in Indonesia
[Picked up by 296 media titles]
2026-06-05 19:08
DayOne Data Centers Announces Final Closing of its Series C Equity Financing at US$4.5 Billion
[Picked up by 294 media titles]
2026-06-05 15:00FPT and NVIDIA Collaborate to Release the Nemotron Personas Vietnam Datasets
[Picked up by 280 media titles]
2026-06-05 17:34
Pudu Robotics and Shenzhen CTID Co. Ltd Launch the World's First Full-Scenario Robot-Serviced Hotel Project
[Picked up by 275 media titles]
2026-06-01 18:00Most Read
WePlay Korea's 4th Anniversary Celebration Kicks Off, Joining Hands with "Hello Panda-哈啰潘达" to Create Fu Bao Themed Space Decorations
2026-06-01 12:00
8425
YY Group (NASDAQ: YYGH) Wins Prestigious HAPA Solutions Excellence Award, Validating Enterprise AI Marketplace Adoption in Southeast Asia
2026-06-05 19:37
8033
Dreame ranked No.1 in Global Robot Vacuum Sales & Revenue, according to International Data Corporation (IDC)
2026-06-05 21:05
7927
